: iStockAnalyst.com Symbols Feed

Analyst Comments: AGIX, Scientific Games, Sohu.com, Barclays, COSI, Cleveland-Cliffs,Potash Corp, Freddie Mac, OSI Pharma

Wed, 08 Oct 2008 12:39:00 GMT

For those of you still holding onto AtheroGenics (AGIX), the research-based pharmaceutical company with two clinical-stage drug development programs (according to Zacks senior drug industry analyst Jason Napodano, CFA, who published a report on AGIX last week), the company has just announced today it has filed for Chapter 11 bankruptcy. The question now seems to be who, if anyone, will pick up the pieces of the late-phase candidates AGIX had been developing.? But for anyone shocked by today's announcement, they shouldn't be.? From the same AGIX report: "The company recently released phase III data on lead compound AGI-1067 that did not meet the primary end point." And this: "In September 2008 AtheroGenics announced it will not repay the its 4.5% Convertible Notes due September 2, 2008, nor will it make its scheduled[More...]

Analyst Comments: AtheroGenics, Toyota, Jamba, GlaxoSmithKline, Metabasis, AFLAC, Crown Castle, Epicor, Amylin Pharma, CNOOC, Skyworks, Tejon

Thu, 02 Oct 2008 12:28:00 GMT

AtheroGenics (AGIX) just reported that top-line ANDES data showed a dose dependent response and statistically significant reduction in A1c at the six month period. However, we would categorize the reduction as only modest at 0.6% for the highest (150mg) dose, and continued signs of elevate liver activity give us cause to remain skeptical of the eventual commercial potential of AGI-1067. Until a large development partner validates the program we choose to remain skeptical of AGI-1067. We are still not comfortable with the side effect profile on it, and with recent topline efficacy data showing only modest reduction in A1c levels, we are struggling to find exactly what differentiating characteristics AGI-1067 will contain in the approved label relative to other oral anti-diabetic medications. Additionally, the dwindling cash position and[More...]

Analyst Comments: AtheroGenics, ConocoPhillips, Carnival Corporation, Zions Bank, Chevron

Thu, 12 Jun 2008 14:29:19 GMT

Interim data for AtheroGenics, Inc.'s (AGIX) AGI-1067 in type 2 diabetes presents a mixed bag in our view. The data is good enough to continue the program and keep management and investors interested in the drug. However, the only modest efficacy and stil[More...]

Analyst Comments: Monarch Casino, Plexus, Crown Castle, Ctrip.com, AtheroGenix, Arch Coal, Logitech, McClatchy

Fri, 25 Apr 2008 16:45:12 GMT

We maintain our Hold rating on shares of Monarch Casino & Resort (MCRI) following the release of disappointing first quarter results. We continue to believe that shares of MCRI hold significant long-term value. That said, in light of the challenging operating environment faced by the company, we do not expect significant near-term share price appreciation. We believe that shares of Monarch are fairly valued at current levels, given the numerous challenges facing the company in the near-term. The company has a proven track record of delivering increasing revenues, earnings, and EBITDA from its...[More...]

Analyst Comments: ConEd, Sempra Energy, Hawaiian Electric, AK Steel Holding, CACI International, Magna International, AtheroGenics, Potash

Tue, 15 Apr 2008 00:44:04 GMT

Stable, regulated utility operations, a strong balance sheet, regulated rate increases, earnings from non-regulated businesses and an increased dividend payout collectively make Consolidated Edison, Inc., a.k.a., ConEd (ED) a conservative income-based inv[More...]

Analyst Comments: PepsiCo, Baidu, Penn Virginia, AtheroGenics, DIRECTV, Baker Hughes,

Tue, 19 Feb 2008 15:09:09 GMT

Strong international growth, productivity improvements, an aggressive share repurchase program, and a strong new product pipeline are driving low double-digit earnings growth for PepsiCo, Inc. (PEP). Nevertheless, a sluggish domestic carbonated beverage environment, modest low-single digit volume growth at Frito-Lay (3% in both 2006 and...[More...]

AtheroGenics Receives Delisting Notice From NASDAQ Global Market Due to Chapter 11 Filing

Fri, 10 Oct 2008 21:11:00 GMT

ATLANTA, GA -- -- 10/10/08 -- AtheroGenics, Inc. today reported that it received notification from the Nasdaq Stock Market indicating that the staff of the Nasdaq Stock Market had determined, in accordance with NASDAQ Marketplace Rules 4300, 4450 and IM-4300, that the Company's common stock should be delisted from the Nasdaq Global Market in light of the Company's filing under Chapter 11 of the United States Bankruptcy Code. Trading in the Company's common stock on the Nasdaq Global Market will be suspended at the opening of business on October 14, 2008. The Company expects that its common stock will continue to trade on the over-the-counter market or the Pink Sheets.[More...]

Zacks Analyst Blog Highlights: Wipro, Ltd., Skechers USA, Inc., Coca- Cola Hellenic Bottling Co., Scientific Games Corp. And AtheroGenics, Inc.

Wed, 08 Oct 2008 04:16:00 GMT

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include: Wipro, Ltd. (NYSE: WIT), Skechers USA, Inc. (NYSE: SKX), Coca-Cola Hellenic Bottling Co. (NYSE: CCH), Scientific Games Corp. (Nasdaq: SGMS) and AtheroGenics, Inc. (Nasdaq: AGIX).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

[More...]

AtheroGenics Files for Chapter 11 Bankruptcy

Tue, 07 Oct 2008 10:47:00 GMT

ATLANTA, GA -- -- 10/07/08 -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it has consented to the Involuntary Chapter 7 Petition filed against the Company on September 15, 2008 in the U.S. Bankruptcy Court for the Northern District of Georgia, and has filed to convert the case to a case under Chapter 11 of the United States Bankruptcy Code.[More...]

Zacks Analyst Blog Highlights: Toyota Motor Corp., Jamba, Inc., AtheroGenics, Inc., Vodafone Group Plc. And Xilinx, Inc.

Wed, 01 Oct 2008 20:13:00 GMT

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include: Toyota Motor Corp. (NYSE: TM), Jamba, Inc. (Nasdaq: JMBA), AtheroGenics, Inc. (Nasdaq: AGIX), Vodafone Group Plc. (NYSE: VOD) and Xilinx, Inc. (Nasdaq: XLNX).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

[More...]

AtheroGenics Restructures Board of Directors

Wed, 10 Sep 2008 23:09:00 GMT

ATLANTA, GA -- -- 09/10/08 -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it has restructured its Board of Directors to reduce the number of directors from ten to six in order to better align the size of its Board with the current needs of the Company. Remaining on the Board will be:[More...]

AtheroGenics Seeks to Realign Capital Structure

Tue, 02 Sep 2008 12:35:00 GMT

ATLANTA, GA -- -- 09/02/08 -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported that it will not repay the Company's 4.5% Convertible Notes due today, nor will it make its scheduled interest payment on the 2008 Notes or the 4.5% Convertible Notes due March 1, 2011 . The Company has been attempting to restructure its 2008 Notes prior to their maturity, but was unable to agree on a restructuring on terms acceptable to the Company and the holders of the 2008 Notes. In a related move, AtheroGenics has retained Morgan Stanley to assist it in evaluating restructuring alternatives to its current capital structure. Holders of all three series of convertible notes: the 2008 Notes, the 2011 Notes and the 1.5% Convertible Notes due February 1, 2012 are invited to contact Morgan Stanley for further information.[More...]

AtheroGenics Reports Second Quarter 2008 Financial Results

Tue, 05 Aug 2008 10:55:00 GMT

AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported financial results for the second quarter and six months ended June 30, 2008.[More...]

BeaconEquity.com Issues Technical Trade Alerts on Market Movers: AGIX, APKT, BIOS, NOVA, CNXT, CHRD

Fri, 01 Aug 2008 14:15:00 GMT

BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.[More...]

AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes

Thu, 31 Jul 2008 10:55:00 GMT

AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced top-line results from its ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type 2 diabetes demonstrating that both doses of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin versus placebo at the end of the study's six month dosing regimen.[More...]

AtheroGenics to Report Second Quarter 2008 Financial Results on August 5, 2008

Fri, 25 Jul 2008 11:10:00 GMT

AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its second quarter 2008 financial results on Tuesday, August 5, 2008 before the U.S. financial markets open.[More...]

Form 5 ATHEROGENICS INC For: Dec 31 Filed by: COLONNESE MARK P (10K)

Thu, 05 Feb 2009 20:36:00 GMT

[More...]